Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas
- PMID: 10088554
- DOI: 10.1016/s0046-8177(99)90014-x
Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas
Abstract
Osteonectin, also termed BM40 or SPARC (secreted protein, acidic and rich in cysteine) is a multifunctional glycoprotein involved in tissue mineralization, cell-extracellular matrix interactions as well as angiogenesis. It has been suggested that osteonectin may play a key role in the process of tumoral invasion and metastasis in certain malignancies. In this study, we reviewed the clinical records and the histopathologic slides of 188 thin cutaneous malignant melanomas (< or = 0.75 mm). Among them, 12 cases underwent progression and were selected for the study. Osteonectin expression was investigated by immunohistochemistry in these 12 patients and 24 matched controls who did not undergo progression. Osteonectin staining was correlated with clinical outcome and other clinicopathologic parameters. Progression-free and disease-specific survival rates were calculated with the Kaplan-Meier method and their differences were evaluated by the log rank test. Overall, immunoreactivity for osteonectin was found in 23 (63.8%) cases. Eighteen cases (50%) displayed staining in 1% to 50% of neoplastic cells whereas five cases (13.8%) showed a diffuse positivity in more than 50% of the tumor cells. Osteonectin expression was significantly correlated with risk of progression (P = .01), incidence of distant metastases (P = .005) and survival (P = .03). There was a higher incidence of osteonectin-positive tumors in cases that did experience regional lymph node metastases versus those cases that did not, but that difference did not reach statistical significance (P = .06). No significant correlation was found between osteonectin expression and other clinicopathologic features, including age, sex, site, histotype, Clark's level, presence of regression, presence of inflammatory response, and tumor growth phase. Our data showed that osteonectin expression is a predictor of clinical outcome in thin cutaneous melanomas.
Similar articles
-
Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.Am J Dermatopathol. 1998 Feb;20(1):12-6. doi: 10.1097/00000372-199802000-00003. Am J Dermatopathol. 1998. PMID: 9504663
-
Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.Cancer. 1999 Mar 1;85(5):1067-76. doi: 10.1002/(sici)1097-0142(19990301)85:5<1067::aid-cncr9>3.0.co;2-t. Cancer. 1999. PMID: 10091790
-
Secreted protein acidic and rich in cysteine expression in human colorectal cancer predicts postoperative prognosis.Eur Rev Med Pharmacol Sci. 2015 May;19(10):1803-11. Eur Rev Med Pharmacol Sci. 2015. PMID: 26044224
-
[Prognostic factors in thin cutaneous malignant melanoma].Pathologica. 2002 Dec;94(6):282-9. doi: 10.1007/s102420200051. Pathologica. 2002. PMID: 12540991 Review. Italian.
-
Prognostication in thin cutaneous melanomas.Arch Pathol Lab Med. 2010 Dec;134(12):1758-63. doi: 10.5858/2009-0653-RAR.1. Arch Pathol Lab Med. 2010. PMID: 21128772 Review.
Cited by
-
Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells.Int J Hematol. 2017 May;105(5):587-597. doi: 10.1007/s12185-016-2169-x. Epub 2017 Jan 2. Int J Hematol. 2017. PMID: 28044259
-
MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma.Sci Rep. 2016 May 27;6:26679. doi: 10.1038/srep26679. Sci Rep. 2016. Retraction in: Sci Rep. 2023 Jul 24;13(1):11917. doi: 10.1038/s41598-023-39043-3. PMID: 27230656 Free PMC article. Retracted.
-
Hic-5 regulates extracellular matrix-associated gene expression and cytokine secretion in cancer associated fibroblasts.Exp Cell Res. 2024 Feb 15;435(2):113930. doi: 10.1016/j.yexcr.2024.113930. Epub 2024 Jan 17. Exp Cell Res. 2024. PMID: 38237846 Free PMC article.
-
High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines.Pathol Oncol Res. 2000;6(1):24-6. doi: 10.1007/BF03032654. Pathol Oncol Res. 2000. PMID: 10749584
-
Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth.Mol Cancer Ther. 2006 Oct;5(10):2503-11. doi: 10.1158/1535-7163.MCT-06-0286. Mol Cancer Ther. 2006. PMID: 17041094 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous